Back to top
more

Canopy Growth (CGC)

(Delayed Data from NSDQ)

$1.37 USD

1.37
9,905,682

-0.01 (-0.72%)

Updated Sep 19, 2025 03:59 PM ET

After-Market: $1.38 +0.01 (0.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (151 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -91.67% and 10.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Canopy Growth Corporation (CGC) is Poised for a Turnaround After Losing -32.52% in 4 Weeks

by Zacks Equity Research

Canopy Growth Corporation (CGC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Down -32.59% in 4 Weeks, Here's Why Canopy Growth Corporation (CGC) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Canopy Growth Corporation (CGC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Medtronic (MDT) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of 71.11% and 5.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exagen Inc. (XGN) delivered earnings and revenue surprises of 15.38% and 18.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aveanna (AVAH) delivered earnings and revenue surprises of 16.67% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Perrigo (PRGO) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 2.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Canopy Growth Corporation (CGC) is Poised for a Turnaround After Losing -23.9% in 4 Weeks

by Zacks Equity Research

Canopy Growth Corporation (CGC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Canopy Growth, Green Thumb Industries and AdvisorShares Pure US Cannabis ETF

by Zacks Equity Research

Canopy Growth, Green Thumb Industries and AdvisorShares Pure US Cannabis ETF have been highlighted in this Investment Ideas article.

Bryan Hayes headshot

Pot Stocks Surge on SAFE Banking Act Reintroduction

by Bryan Hayes

Lawmakers are attempting to make a final push toward delivering financial services for the cannabis industry.

Zacks Equity Research

Humana (HUM) Rewards Shareholders With a 12.4% Dividend Hike

by Zacks Equity Research

Humana's (HUM) capital position with strong cash-generating abilities and a solid balance sheet will likely sustain its shareholder-friendly moves.

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -169.23% and 11.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phibro Animal Health (PAHC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Phibro (PAHC) delivered earnings and revenue surprises of 13.33% and 2.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Canopy Growth Corporation (CGC) closed the most recent trading day at $2.38, moving -0.42% from the previous trading session.

Andrew Rocco headshot

Wednesday Recap: Minty Fresh Breadth

by Andrew Rocco

Breadth is an important measure used by investors to determine how strong or weak a market index is beneath the surface. Tuesday, the market flashed very strong breadth - an indication that bulls may be ready to take back the baton.

Zacks Equity Research

Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Canopy Growth Corporation (CGC) closed the most recent trading day at $2.31, moving +1.32% from the previous trading session.

Zacks Equity Research

Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Canopy Growth Corporation (CGC) closed the most recent trading day at $2.33, moving +1.75% from the previous trading session.

Zacks Equity Research

Canopy Growth Corporation (CGC) Stock Moves -0.38%: What You Should Know

by Zacks Equity Research

Canopy Growth Corporation (CGC) closed the most recent trading day at $2.60, moving -0.38% from the previous trading session.

Andrew Rocco headshot

Pot Stocks Get Smoked: What's Behind the Move?

by Andrew Rocco

Marijuana-related stocks reversed gains from earlier in the week as revelations emerged that a recent marijuana bill is unlikely to pass.

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -55.56% and 0.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -12.50% and 0.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for September 30th

by Zacks Equity Research

CGC, ESALY and META have been added to the Zacks Rank #5 (Strong Sell) List on September 30, 2022.